1530 related articles for article (PubMed ID: 24140094)
21. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
22. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.
Leech CA; Dzhura I; Chepurny OG; Kang G; Schwede F; Genieser HG; Holz GG
Prog Biophys Mol Biol; 2011 Nov; 107(2):236-47. PubMed ID: 21782840
[TBL] [Abstract][Full Text] [Related]
23. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.
Drucker DJ
Diabetes; 2013 Oct; 62(10):3316-23. PubMed ID: 23818527
[TBL] [Abstract][Full Text] [Related]
24. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
25. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.
Zhang M; Robitaille M; Showalter AD; Huang X; Liu Y; Bhattacharjee A; Willard FS; Han J; Froese S; Wei L; Gaisano HY; Angers S; Sloop KW; Dai FF; Wheeler MB
Mol Cell Proteomics; 2014 Nov; 13(11):3049-62. PubMed ID: 25044020
[TBL] [Abstract][Full Text] [Related]
26. Incretin actions beyond the pancreas: lessons from knockout mice.
Yabe D; Seino Y
Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
[TBL] [Abstract][Full Text] [Related]
27. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
28. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
29. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
30. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
31. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
32. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1).
Yu Z; Jin T
Cell Signal; 2010 Jan; 22(1):1-8. PubMed ID: 19772917
[TBL] [Abstract][Full Text] [Related]
33. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
34. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
35. Incretins and Their Endocrine and Metabolic Functions.
Seufert J
Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
[TBL] [Abstract][Full Text] [Related]
36. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Doyle ME; Egan JM
Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
[TBL] [Abstract][Full Text] [Related]
38. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
39. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
[TBL] [Abstract][Full Text] [Related]
40. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
